How 23andMe’s Genetic Database Bridges the Gap in Alzheimer’s Research

August 9, 2018

(MD Magazine) – While leading genealogy reporting companies continue to amass valuable stores of genetic data from individuals looking to learn more about their ancestral background, pharmaceutical companies have found a new way to utilize these genetic profiles. For pharmaceutical companies, these massive databases are a veritable goldmine for the research and development of novel therapies for difficult-to-treat neurological conditions. But the question remains of how 2 major entities would share such a mine.

Posted by

Posted in Genetic Ethics, News, Pharma

Recommended Reading